Abstract 384P
Background
Betel nut chewing might contribute to strong invasion and treatment refractoriness. In western countries where HPV+ OPC prevalence is high, induction TPF response rate in locally advanced HNSCC is around 70%; Erbitux and TP (Argiris in JCO2008) response rate is 86%. In the analysis from KGMH in Taiwan, induction response for locally advanced HNSCC was 55% in betel-nuts chewers compared with 75% in non-users(p=0.038; From Su in World Journal of Surgical Oncology 2016). Erbitux-TPF induction response rate was 88% from VGH in Taiwan by Lu in Head & Neck2019. In our previous study from unresectable stage IVA & IVB betal-nuts related HNSCC patients in ASCO2023, flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion) with Biotherapy(EGFR or VEGFR-targeting)or Bio-immunotherapy had encouraging induction response with favorable toxicity to conversion surgery or definite CCRT.
Methods
Hypopharyngreal cancer in Taiwan in Taiwan often had advaced stage(stage IV 70%) and double cancers easily(esp. lung cancer and esophageal cancer). We prepared to compare the outcomes of different treatment strategies in stage IVA/IVB hypophryngeal cancer, from 2012 to 2023.
Results
Table: 384P
Treatment strategies(total 75 patients) | Definite CCRT 9 | Curative surgery then adjuvant CCRT 14(all receiving total laryngectomy & bilateral neck dissection) | Induction therapy then definite CCRT 29 | Induction therapy then curative surgery then adjuvant CCRT 23 |
Induction response(total 52 patients) | N/A | N/A | 69%(20/29) | 87%(20/23) |
2-year DFS(total 64 patients) | 57.1% | 63.6% | 68% | 81% |
5-year OS(total 50 patients) | 20% | 26.7% | 37.5% | 50% |
All with maintenance UFUR
Conclusions
CCRT is still one standard option; if no need for organ preservation, curative surgery followed by adjuvant CCRT still works in resectable and medically operable patients. Maintenance UFUR yielded relatively favorable 2-year DFS and 5-year OS. Induction Bio-CT or Bio-chemoimmunotherapy followed by CCRT may be promoted beyond TAX323/324. Aggressive induction therapy followed by mini-invasive surgery and then adjuvant CCRT with maintenance UFUR might be administered in selected patients with high induction response. Encouraging outcomes have been shown by sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board in National Taiwan University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract